Clinical characteristics and bisphosphonates treatment of rare pregnancy- and lactation-associated osteoporosis

Lu‐Jiao Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Mei Li(Yantaishan Hospital), Weibo Xia(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Peng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Jia Zhang(Aerospace Center Hospital), Dichen Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuwen Song(Chinese Academy of Medical Sciences & Peking Union Medical College), Ou Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Fang Lv(Liaoning Normal University), Xiaoyan Chang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoping Xing(Chinese Academy of Medical Sciences & Peking Union Medical College)
Clinical Rheumatology
June 26, 2018
10.1007/s10067-018-4185-0
Cited by 48

Related Papers

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies
|Journal of Nanoparticle Research|2014|128
CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells
|Journal of Experimental & Clinical Cancer Research|2022|115
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis
|Bone|2019|110
The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles
|Medicine|2017|100